Summary
5.67 0.60(11.83%)09/16/2024
Concord Medical Services (CCM)
Concord Medical Services (CCM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 11.83 | 8.00 | -23.27 | 877.59 | 1,160.28 | 336.15 | -70.10 | 236.33 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.67 | |
| Open | 5.00 | |
| High | 6.17 | |
| Low | 5.00 | |
| Volume | 13,500 | |
| Change | 0.60 | |
| Change % | 11.83 | |
| Avg Volume (20 Days) | 9,893 | |
| Volume/Avg Volume (20 Days) Ratio | 1.36 | |
| 52 Week Range | 0.38 - 9.80 | |
| Price vs 52 Week High | -42.14% | |
| Price vs 52 Week Low | 1,392.11% | |
| Range | 13.40 | |
| Gap Up/Down | -0.39 | |
Fundamentals | ||
| Market Capitalization (Mln) | 24 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 1.20 | |
| Book Value | 2.8080 | |
| Earnings Per Share | -2.5450 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -2.5450 | |
| Revenues | ||
| Profit Marging | -0.8157 | |
| Operating Marging (TTM) | -0.9957 | |
| Return on asset (TTM) | -0.0360 | |
| Return on equity (TTM) | -0.1495 | |
| Revenue TTM | 332,887,008 | |
| Revenue per share TTM | 7.5970 | |
| Quarterly Revenue Growth (YOY) | 1.3240 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 13,083,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.0038 | |
| Revenue Enterprise Value | 1.8536 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 43,417,200 | |
| Shares Float | 13,383,220 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 18.00 | |
| Institutions (%) | 0.64 | |
09/16 08:00 EST - prnewswire.com
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING , Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING , Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
08/07 08:30 EST - prnewswire.com
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING , Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement"). As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary Shares.
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING , Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement"). As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary Shares.
07/11 16:00 EST - prnewswire.com
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING , July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares (the "ADS Ratio") from the current ADS Ratio of one (1) ADS representing three (3) Class A ordinary shares to a new ADS Ratio of one (1) ADS representing thirty (30) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on July 30, 2024 (U.S. Eastern Time).
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING , July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares (the "ADS Ratio") from the current ADS Ratio of one (1) ADS representing three (3) Class A ordinary shares to a new ADS Ratio of one (1) ADS representing thirty (30) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on July 30, 2024 (U.S. Eastern Time).
06/13 18:05 EST - businesswire.com
Canagold Resources Ltd. Announces Voting Results From Annual General Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company”) announces that at its annual general meeting of shareholders held on June 12, 2024 (the “Meeting”), all directors listed in the Information Circular dated May 9, 2024 were elected. The detailed results are as follows: Nominee Director Votes For % Votes For Votes Withheld % Votes Withheld Sofia Bianchi 93,941,380 99.46 511,258 0.54 Kadri Dagdelen 94,112,959 99.64 339,6.
Canagold Resources Ltd. Announces Voting Results From Annual General Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company”) announces that at its annual general meeting of shareholders held on June 12, 2024 (the “Meeting”), all directors listed in the Information Circular dated May 9, 2024 were elected. The detailed results are as follows: Nominee Director Votes For % Votes For Votes Withheld % Votes Withheld Sofia Bianchi 93,941,380 99.46 511,258 0.54 Kadri Dagdelen 94,112,959 99.64 339,6.
06/05 07:30 EST - businesswire.com
Canagold Initiates Resource Expansion Drilling at New Polaris Project
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce that, in line with its commitment to accelerating the advancement of the New Polaris Gold project towards production, drill crews have been mobilized to the site in northern British Columbia to restart drilling operations. The 2024 drilling program includes 12,000 meters of drilling, primarily targeting high-grade mineralization a.
Canagold Initiates Resource Expansion Drilling at New Polaris Project
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce that, in line with its commitment to accelerating the advancement of the New Polaris Gold project towards production, drill crews have been mobilized to the site in northern British Columbia to restart drilling operations. The 2024 drilling program includes 12,000 meters of drilling, primarily targeting high-grade mineralization a.
04/19 08:31 EST - prnewswire.com
Concord Medical Files 2023 Annual Report on Form 20-F
BEIJING , April 19, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.
Concord Medical Files 2023 Annual Report on Form 20-F
BEIJING , April 19, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.
03/28 15:38 EST - businesswire.com
Canagold Resources Ltd. Announces Closing of $4.1M Charity Flow Through Financing
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the "Company" or "Canagold"), is pleased to announce it has closed a charity flow-through financing with Sun Valley Investments AG (“Sun Valley”). The Company issued 15,700,000 common shares of the Company (the “FT Share”) that qualify as flow-through shares for the purposes of the Income Tax Act (Canada) at a price of $0.2625 per FT Share for total gross proceeds of $4,121,500 (the.
Canagold Resources Ltd. Announces Closing of $4.1M Charity Flow Through Financing
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the "Company" or "Canagold"), is pleased to announce it has closed a charity flow-through financing with Sun Valley Investments AG (“Sun Valley”). The Company issued 15,700,000 common shares of the Company (the “FT Share”) that qualify as flow-through shares for the purposes of the Income Tax Act (Canada) at a price of $0.2625 per FT Share for total gross proceeds of $4,121,500 (the.
02/20 07:00 EST - prnewswire.com
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
BEIJING , Feb. 20, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter (the "Letter") from the New York Stock Exchange (the "NYSE") dated February 12, 2024, notifying the Company that it is below compliance standards due to the trading price of the Company's American depositary shares (the "ADSs") and that the applicable cure period for the Company to regain compliance expires on August 12, 2024. Pursuant to applicable NYSE continued listing standards, a company would be considered "below criteria" by the NYSE if the average closing price of a security as reported on the consolidated tape is less than $1.00 over a consecutive 30 trading-day period.
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
BEIJING , Feb. 20, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter (the "Letter") from the New York Stock Exchange (the "NYSE") dated February 12, 2024, notifying the Company that it is below compliance standards due to the trading price of the Company's American depositary shares (the "ADSs") and that the applicable cure period for the Company to regain compliance expires on August 12, 2024. Pursuant to applicable NYSE continued listing standards, a company would be considered "below criteria" by the NYSE if the average closing price of a security as reported on the consolidated tape is less than $1.00 over a consecutive 30 trading-day period.
01/09 07:00 EST - prnewswire.com
Concord Medical Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited
BEIJING , Jan. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), its subsidiary, at an initial public offer price of HK$14.28 per H share on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK.
Concord Medical Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited
BEIJING , Jan. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced the listing of a minority stake of 39,420,200 H shares in Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), its subsidiary, at an initial public offer price of HK$14.28 per H share on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK.
01/04 07:30 EST - businesswire.com
Canagold Appoints Chris Pharness as Senior Vice President Sustainability and Permitting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (“Canagold” or the “Company”) announces today that the Company has appointed Mr. Chris Pharness as Senior Vice President Sustainability and Permitting, effective immediately. Mr. Pharness has 30 years of experience as an Environmental Professional. He has a proven record of success in community engagement, relationship building and negotiation, and demonstrated achievement in project.
Canagold Appoints Chris Pharness as Senior Vice President Sustainability and Permitting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (“Canagold” or the “Company”) announces today that the Company has appointed Mr. Chris Pharness as Senior Vice President Sustainability and Permitting, effective immediately. Mr. Pharness has 30 years of experience as an Environmental Professional. He has a proven record of success in community engagement, relationship building and negotiation, and demonstrated achievement in project.
11/20 16:00 EST - prnewswire.com
Concord Medical Schedules 2023 Annual Meeting of Shareholders
BEIJING , Nov. 20, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2023 annual general meeting of shareholders (the "Meeting") on December 26, 2023, at 10:00 a.m. (Beijing Time).
Concord Medical Schedules 2023 Annual Meeting of Shareholders
BEIJING , Nov. 20, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2023 annual general meeting of shareholders (the "Meeting") on December 26, 2023, at 10:00 a.m. (Beijing Time).
09/22 17:00 EST - prnewswire.com
Concord Medical Reports Financial Results for the First Half of 2023
BEIJING , Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023 [1].
Concord Medical Reports Financial Results for the First Half of 2023
BEIJING , Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023 [1].
08/11 09:25 EST - headlinesoftoday.com
Cincom® Integrates with Duck Creek to Streamline Customer Communication Processes for Insurers
CINCINNATI, Aug. 11, 2022 /PRNewswire/ — Cincom Systems®, a global provider of Customer Communications Management (CCM) solutions, announced today it has integrated with Duck Creek’s insurance suite to help insurers accelerate the digital transformation of their customer communications processes across the entire customer lifecycle. The combined power of Duck Creek and Cincom Eloquence® enables insurers […]...
Cincom® Integrates with Duck Creek to Streamline Customer Communication Processes for Insurers
CINCINNATI, Aug. 11, 2022 /PRNewswire/ — Cincom Systems®, a global provider of Customer Communications Management (CCM) solutions, announced today it has integrated with Duck Creek’s insurance suite to help insurers accelerate the digital transformation of their customer communications processes across the entire customer lifecycle. The combined power of Duck Creek and Cincom Eloquence® enables insurers […]...
07/24 22:10 EST - headlinesoftoday.com
FUJIFILM Business Innovation Hong Kong and Quadient Celebrate 10-year Partnership
60% of customer communication management (CCM) solutions portfolio from FUJIFILM Business Innovation Hong Kong and Quadient are international insurance companies. HONG KONG, July 25, 2022 /PRNewswire/ — Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, and FUJIFILM Business Innovation Hong Kong Limited (FUJIFILM BI Hong Kong), a […]...
FUJIFILM Business Innovation Hong Kong and Quadient Celebrate 10-year Partnership
60% of customer communication management (CCM) solutions portfolio from FUJIFILM Business Innovation Hong Kong and Quadient are international insurance companies. HONG KONG, July 25, 2022 /PRNewswire/ — Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, and FUJIFILM Business Innovation Hong Kong Limited (FUJIFILM BI Hong Kong), a […]...
11/10 13:28 EST - pymnts.com
Presto Completes $1B SPAC Merger to Go Public
Restaurant-technology startup Presto will have a valuation of about $1 billion when it goes public through special purpose acquisition company (SPAC) Ventoux CCM Acquisition Corp., the companies told The Wall Street Journal Wednesday (Nov. 10). The $170 million Ventoux CCM SPAC, which is led by former hospitality execs and backed by investment bank Chardan Capital […]
Presto Completes $1B SPAC Merger to Go Public
Restaurant-technology startup Presto will have a valuation of about $1 billion when it goes public through special purpose acquisition company (SPAC) Ventoux CCM Acquisition Corp., the companies told The Wall Street Journal Wednesday (Nov. 10). The $170 million Ventoux CCM SPAC, which is led by former hospitality execs and backed by investment bank Chardan Capital […]
10/18 04:08 EST - prnewswire.com
Concord Medical Is Shortlisted for the "5G+Healthcare" Pilot Project
BEIJING, Oct. 18, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that two projects of it, Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform ("Jiahe Cloud") and Jiahe Feiyun Intelligent Radiotherapy Cloud Service Platform ("Jiahe Feiyun"), were successfully shortlisted by the "5G+Healthcare" pilot project, which is launched by Ministry of Industry and Information Technology. Jiahe Cloud provides digitized solutions, with remote diagnosis as the core service, for medical institutions.
Concord Medical Is Shortlisted for the "5G+Healthcare" Pilot Project
BEIJING, Oct. 18, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that two projects of it, Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform ("Jiahe Cloud") and Jiahe Feiyun Intelligent Radiotherapy Cloud Service Platform ("Jiahe Feiyun"), were successfully shortlisted by the "5G+Healthcare" pilot project, which is launched by Ministry of Industry and Information Technology. Jiahe Cloud provides digitized solutions, with remote diagnosis as the core service, for medical institutions.
10/15 18:00 EST - prnewswire.com
Concord Medical Files 2020 Annual Report on Form 20-F
BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.
Concord Medical Files 2020 Annual Report on Form 20-F
BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.
09/10 07:02 EST - prnewswire.com
Concord Medical Purchases Additional Proton Therapy System for It's Shanghai Concord Cancer Center
BEIJING, Sept. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that Shanghai Concord Cancer Center ("SCCC", or the "planned hospital"), a business subsidiary of an important operating platform of the Company, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd.
Concord Medical Purchases Additional Proton Therapy System for It's Shanghai Concord Cancer Center
BEIJING, Sept. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that Shanghai Concord Cancer Center ("SCCC", or the "planned hospital"), a business subsidiary of an important operating platform of the Company, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd.
08/23 06:10 EST - prnewswire.com
Concord Medical Completes RMB 400 Million Funding Round Led by Consortium Investors
BEIJING, Aug. 23, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializes in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced an investment of RMB400.0 million (US$62.2 million) in Concord Medical's subsidiary, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd. ("Meizhong Jiahe") from several investors led by WisdoMont Asset Management (Shanghai) Co., Ltd.
Concord Medical Completes RMB 400 Million Funding Round Led by Consortium Investors
BEIJING, Aug. 23, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializes in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced an investment of RMB400.0 million (US$62.2 million) in Concord Medical's subsidiary, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd. ("Meizhong Jiahe") from several investors led by WisdoMont Asset Management (Shanghai) Co., Ltd.
06/11 06:11 EST - prnewswire.com
Concord Medical Officially Opens New Specialty Cancer Hospital in Guangzhou
BEIJING, June 11, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that its Guangzhou Concord Cancer Center ("GCCC"), which is certified as a tertiary specialty hospital by the National Health Commission, is now in operation. This has marked a major milestone for the Company.
Concord Medical Officially Opens New Specialty Cancer Hospital in Guangzhou
BEIJING, June 11, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that its Guangzhou Concord Cancer Center ("GCCC"), which is certified as a tertiary specialty hospital by the National Health Commission, is now in operation. This has marked a major milestone for the Company.